Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based Resid...Siobhan Morse
Prior research in this population suggests that, overall, opiate and non-opiate addicted users have different issues and ought to be treated differently for their addiction—and that young and older adult opiate users present at treatment with different issues. This study investigated what significant differences in treatment motivation, length and outcome, if any, exist between opiate and non-opiate users and further investigates young adult (18-25 years of age) and older adult (26 and older) opiate users and the impact of any differences. Data for this study was drawn from 1972 individuals who entered voluntary, private, residential drug treatment and rehab. Study measures included the Addiction Severity Index (ASI), the Treatment Service Review (TSR), and the University of Rhode Island Change Assessment (URICA). Interviews were conducted at program intake and six-months post-discharge. Implications for addiction treatment providers and planners are discussed.
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...Epstein Becker Green
Presented by David Shillcutt (Associate, Epstein Becker Green) and Kristina Sherry (Attorney, Nelson Hardiman) on April 4, 2019.
Office-based opioid treatment providers are on the front lines of the response to the opioid epidemic, but recent developments in federal and state legislation have significant implications for provider business models and service delivery strategies.
This webinar will examine provider capacity issues for medication assisted treatment, the opportunities and challenges of telemedicine for addiction services, and the expansion of innovative service delivery networks including the “Hub and Spoke” system and related models.
Part of a "first Thursdays" webinar series hosted by Behavioral Health Association of Providers, Epstein Becker & Green, P.C., and Nelson Hardiman, LLP.
More info: https://www.ebglaw.com/events/office-based-opioid-treatment-what-you-need-to-know-trends-in-behavioral-health-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based Resid...Siobhan Morse
Prior research in this population suggests that, overall, opiate and non-opiate addicted users have different issues and ought to be treated differently for their addiction—and that young and older adult opiate users present at treatment with different issues. This study investigated what significant differences in treatment motivation, length and outcome, if any, exist between opiate and non-opiate users and further investigates young adult (18-25 years of age) and older adult (26 and older) opiate users and the impact of any differences. Data for this study was drawn from 1972 individuals who entered voluntary, private, residential drug treatment and rehab. Study measures included the Addiction Severity Index (ASI), the Treatment Service Review (TSR), and the University of Rhode Island Change Assessment (URICA). Interviews were conducted at program intake and six-months post-discharge. Implications for addiction treatment providers and planners are discussed.
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...Epstein Becker Green
Presented by David Shillcutt (Associate, Epstein Becker Green) and Kristina Sherry (Attorney, Nelson Hardiman) on April 4, 2019.
Office-based opioid treatment providers are on the front lines of the response to the opioid epidemic, but recent developments in federal and state legislation have significant implications for provider business models and service delivery strategies.
This webinar will examine provider capacity issues for medication assisted treatment, the opportunities and challenges of telemedicine for addiction services, and the expansion of innovative service delivery networks including the “Hub and Spoke” system and related models.
Part of a "first Thursdays" webinar series hosted by Behavioral Health Association of Providers, Epstein Becker & Green, P.C., and Nelson Hardiman, LLP.
More info: https://www.ebglaw.com/events/office-based-opioid-treatment-what-you-need-to-know-trends-in-behavioral-health-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
Addiction Medicine: Closing the Gap between Science and PracticeCenter on Addiction
These slides accompany CASAColumbia's report, Addiction Medicine: Closing the Gap between Science and Practice, published in June 2012, which found that, despite the prevalence of addiction, the enormity of its consequences, the availability of effective solutions and the evidence that addiction is a disease, both screening and early intervention for risky substance use are rare, and only about 1 in 10 people with addiction involving alcohol or drugs other than nicotine receive any form of treatment.
Vision Session: U.S. Office of Inspector General - From Analytics to Action: A Law Enforcement Perspective on the Use of Data Analytics to Combat Rx Drug Diversion
Received some messages on Medication Assisted Treatment (MAT) where we discussed the confusion around why MAT is an evidenced based practice and why abstinence is not always the best indicator of recovery and wellness. MAT is teh GOLD standard and works!!! We have a tool to treat addiction! Thanks for the discussion! Learn more and explore this interactive powerpoint with a great teacher: Dr. Williams,
Mystified by MAT? Navigating the Changing Regulatory Landscape Around Medicat...Epstein Becker Green
Part of a "first Thursdays" fall webinar series hosted by Behavioral Health Association of Providers, Epstein Becker & Green, P.C., and Nelson Hardiman, LLP.
Presented by:
Francesca R. Ozinal – Associate, Epstein Becker Green
Andrew Martin – Chief Operating Officer, Behavioral Health Association of Providers
Despite reports identifying medication-assisted treatment (MAT) as a critical element of evidence-based treatment, confusion concerning who may dispense, associated compliance requirements, and the relationship between MAT provision and behavioral health providers continues to impede access to MAT.
This webinar will review key licensing and operational issues concerning the various types of MAT, including buprenorphine, naltrexone, and methadone, as well as misperceptions and key compliance issues in instituting MAT.
More info: https://www.ebglaw.com/events/mystified-by-mat-navigating-the-changing-regulatory-landscape-around-medication-assisted-treatment/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
Goals: The goal of this training is to help participants develop their knowledge, skills and abilities as Substance Use Screenng, Brief Intervention, and Referral to Treatment (SBIRT) Trainers.
At the end of this training participants will be able to understand the information screening does and does not provide,define brief intervention, describe the goals of conducting a BI, understand the counselor's role in providing BI, describe referral to treatment, identify SBIRT as a system change initiative, introduce the public health approach, and understand the continuum of substance use.
Audience: Social Workers, counselors and other behavioral health providers from all settings can benefit from understanding substance use across a continuum and its impact on clients behavioral health and other psychosocial interactions.
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
1. Addiction Is A Disease, Not A Choice,
And Should Be Treated As Such
Presenters:
Genie L. Bailey, MD, DABAM, Associate Clinical Professor of
Psychiatry and Human Behavior at Brown University
Van Ingram, Executive Director of the Kentucky Office of
Drug Control Policy
Frank Vocci, PhD, President of Friends Research Institute
2. Disclosure Statements
• CLAAD’s funders include members of the
pharmaceutical, addiction treatment, and
laboratory industries, and are disclosed on its
website, www.claad.org.
• CLAAD is managed by DCBA Law & Policy. To
avoid conflicts of interest, DCBA adheres to
the District of Columbia Rules of Professional
Conduct §§ 1.7-1.9.
3. Disclosure Statements
• Genie L. Bailey’s institution has received grant support from NIDA, Reckitt-
Benckiser (Indivior) and Braeburn Pharmaceuticals. She has received drug
study in-kind support from Reckitt-Benckiser (Indivior). Dr. Bailey has received
travel support from BioDelivery Sciences International, Inc. and is on the
advisory boards of Braeburn Pharmaceuticals; BioDelivery Sciences
International, Inc.; and Camurus AB. She is on the speakers’ bureau of
BioDelivery Sciences International, Inc.
• Van Ingram has no relevant, real or apparent, personal or professional,
financial relationships with proprietary entities that produce health care goods
and services.
• Frank Vocci has consulted with and received reimbursement for meals and
travel expenses from the following companies: Braeburn Pharmaceuticals,
Demerx, Indivior, and Pinney Associates. He has received travel and meal
expenses from Intratab Labs Inc., and received consulting fees from Alkermes
and Usona Institute. All of Dr. Vocci’s consulting fees go to Friends Research
Institute, Inc.
4. Introduction
• Reductions in supply of medications available for abuse
must be matched by corresponding decreases in demand
• A substance use disorder (SUD) is a disease of the brain and
should be treated as such (NIDA 2015)
• Medication-assisted treatment (MAT) has been shown to
be safe and effective in treating SUDs (HHS, 2015)
• MAT has been shown to be effective in treating opioid use
disorders and reducing drug-related disease and criminal
recidivism (HHS, 2010)
• SUDs exact over $700 billion annually in costs related to
crime, lost work productivity, and health care (NIDA 2015)
5. Need for Greater Demand Reduction
Rx drug overdose deaths increased
2.8 fold between 2001 and 2014
>10,500 heroin-related deaths in
2014; quadrupled between 2002
and 2014
6. Need for Greater Demand Reduction
• Rx opioid-overdose deaths increased 9%
between 2013 & 2014 (CDC 2015)
– Increase likely due to illicit synthetic fentanyl (RADARS,
2015)
• Major drivers of recent heroin use increases &
related deaths
– Increased accessibility
– Lower market price
– High purity
7. State Efforts To Reduce Supply Yield
Progress
• Policy measures
– State-wide opioid prescribing guidelines
– Mandatory prescriber education
– Requiring pain clinics treating with controlled substances to register
with state
– 49 states and D.C. have prescription drug monitoring programs
(PDMPs)
– 29 states require prescriber or dispenser to check PDMP
• Decrease in deaths and hospitalizations in locations that
implemented policies to address rx opioid abuse
– 27% decrease in overdose deaths in FL between 2010 and 2012
– 29% decrease in overdose deaths in Staten Island between 2011 to
2013
– 11% decrease in hospitalizations for overdoses in KY in 2013
8. How To Reduce Demand
• Prevention
– Public awareness
– Prescriber education (also reduces supply)
– Patient counseling
• Therapeutic screenings and interventions for
substance use (e.g., SBIRT)
• Individualized treatment for SUDs
9. SUD Is a Brain Disease
• A chronic, relapsing brain disease that causes
compulsive drug seeking and use, despite harmful
consequences (NIDA 2014)
• Similar to other chronic, relapsing diseases (e.g.,
diabetes, asthma, heart disease)
• Can be managed successfully with treatment (NIDA 2014)
• Relapse
– Not uncommon
– Does not signal treatment failure
– Indicates treatment should be reinstated or adjusted or
alternative treatment is needed
10. Medication-Assisted Treatment
• An evidence-based method that combines
counseling, behavioral therapies, and FDA-
approved meds to treat SUDs
• Approved meds for opioid use disorders
– Methadone (opioid full agonist) – available at
federally regulated opioid treatment programs (OTPs)
– Naltrexone (non-opioid) – available in physician
offices
– Buprenorphine (opioid partial agonist) – available in
physician offices and OTPs
11. Treatment: Effectiveness
• MAT effective in
– Treating opioid use disorders
– Reducing drug-related disease, criminal recidivism, and
morbidity and mortality
– Increasing quality of life (HHS)
• Why?
– Long-lasting changes in brain chemistry can cause difficulty with
abstaining from opioid use; withdrawal symptoms and cravings
can be overwhelming
– MAT can help reduce withdrawal symptoms and curb opioid
cravings that can lead to relapse
– Long-term MAT has greater than 85% chance of reducing overall
mortality among people with opioid use disorders (British Medical
Journal, 2010)
12. Treatment: Research
• Novel meds to treat SUDs are under development
– Six-month subdermal buprenorphine implant for
maintenance treatment of opioid use disorders (action
expected 5/27/16)
– Buprenorphine once-monthly or once-weekly
injectable, each with multiple doses, to cover
initiation through maintenance (phase III)
– Vaccine to prevent synthetic opioids from reaching
brain (The Scripps Research Institute, 2016)
– Hydromorphone NME prodrug (IND filed)
• Designed not to release until metabolized in GI tract
• Clinical program to assess potential to limit oral abuse and
overdose
13. Access to Treatment: Coverage
• Private payers
– Insurers using loopholes to deny coverage (e.g., step therapy – outpatient
before inpatient, cancel coverage after pre-approval, require proof of payment
in full, checks to patients)
• Medicare Advantage plans must ensure access to MAT; prior auth &
adverse tiering requirements prohibited b/c they duplicate DATA 2000 &
REMS safeguards (CMS 2016)
• Medicaid: 2013 ASAM study found widespread problems with MAT access
among Medicaid programs
– Limits on dosage; lifetime limits on MAT, complex prior auth, limits on refills
• Incarcerated individuals
– Private insurance, Medicare, and Medicaid not available to incarcerated
individuals
– Prisons denying MAT to inmates; in Feb. 2015, Obama Administration
announced no fed. funding for drug courts denying access to meds
– 5% die of overdose within two weeks of release from prison
• Learn more on Tuesday at 12:30 at “Ensuring Access to Quality Treatment”
14. Access to Treatment: Federal Law
• Drug Addiction Treatment Act of 2000 (DATA 2000) - 30/100 limit
• HHS to revise regs to expand buprenorphine access (expected 4/8/2016)
• The Recovery Enhancement for Addiction Treatment (TREAT) Act, S.
1455 (Sen. Ed Markey (MA))
– Physicians: treat 100 year 1; unlimited after if:
• Certified & agree to participate in PMP; or
• Obtain 24 hrs of training, agree to participant in PMP, and practice in qualified
setting
– Nurse practitioners & physician assistants to prescribe to 100 pts if:
• Licensed to prescribe c.s. for pain, under physician supervision, training, and
practice in qualified setting (NP only)
• Proposal to provide exemptions for injectables & implantables if
treatment is formulated to last 7 days or more and administered
directly to patient (Sen. Rand Paul (KY))
• Barrier based on duration of treatment during clinical studies
15. Criminal Justice Reform
• Untreated substance use costs $600 billion annually
– $8.2 billion in criminal justice costs
• Cost savings from substance use treatment
– $1 invested = $4 return in health care costs + $7 in law
enforcement & other criminal justice costs
• In 2010, 2.7 mill. U.S. prison inmates (85%) abused
controlled substances
• Only 11% with SUDs receive treatment in prison
• Estelle v. Gamble (Supreme Ct. case from 1976):
inadequate medical care for inmates is
unconstitutional
16. Criminal Justice Reform
• Innovative sheriffs and police chiefs
– TN detention center & recovery center partnership to
provide MAT for pregnant women to prevent effects of
harmful detox
– Worcester County Sheriff’s office received $750K federal
grant to provide substance use and mental health
treatment along with numerous additional pre-release
services to inmates
– Angel Initiative in Gloucester, MA and Operation Hope in
Scarborough, ME allows people with opioid use disorders
to walk into a police station and ask for help
– LEAD in Seattle, WA diverts low-level drug and prostitution
offenders into community-based treatment and support
services instead of jail and prosecution
17. Criminal Justice Reform
• Policy Recommendations
– Provide effective treatment for incarcerated
individuals
– Re-entry and recovery support to reduce
recidivism
– Sen. Ed Markey (MA) legislation: The Supporting
Positive Outcomes After Release Act of 2015
• Suspend (not terminate) Medicaid while incarcerated
• Enable incarcerated individuals to access services more
quickly upon re-entry